前列腺内优势结节50 Gy立体定向体部放疗:1a/1b期试验结果
本研究为1a/1b期试验,对局限性前列腺癌患者全前列腺给予36.25 Gy/5次立体定向极低分次放疗,同时将磁共振可见的前列腺内优势结节剂量递增至45 Gy、47.5 Gy和50 Gy。1a期9例未观察到剂量限制性毒性,未达最大耐受剂量;1b期扩展队列11例在50 Gy剂量水平未报告≥3级毒性,并观察到部分患者产生抗原特异性免疫反应。
要点
- 1a期9例在45 Gy、47.5 Gy和50 Gy剂量水平均未观察到剂量限制性毒性,未达最大耐受剂量。
- 1b期扩展队列11例在50 Gy剂量水平未报告≥3级胃肠或泌尿生殖毒性。
- 50 Gy组部分患者产生针对前列腺特异性膜抗原(n=2)、前列腺酸性磷酸酶(n=1)、前列腺干细胞抗原(n=4)和前列腺特异性抗原(n=2)的抗原特异性免疫反应。
核心结论
- 全前列腺36.25 Gy/5次放疗并将前列腺内优势结节剂量递增至50 Gy可耐受,确定为1b期推荐剂量。
- 该治疗显示出有前景的抗肿瘤活性,将通过正在进行的2期部分加以确认。
- 初步生活质量分析显示对泌尿生殖、胃肠和性功能领域影响轻微。
- 立体定向照射在部分患者中诱导了抗原特异性免疫反应。
研究设计与样本
- 1a/1b期试验,采用「3+3」队列剂量递增设计确定1b期推荐剂量。
- 入组局限性前列腺癌患者,全前列腺给予36.25 Gy/5次,同时将磁共振可见的前列腺内优势结节递增至45 Gy、47.5 Gy和50 Gy(均5次)。
- 1a期9例接受治疗;1b期扩展队列11例在最高剂量水平(50 Gy)接受照射。
- 主要终点为首次放疗分次后90天内美国国家癌症研究所常见不良事件术语标准(版本4)≥3级胃肠或泌尿生殖毒性(或两者)定义的剂量限制性毒性。
- 次要终点为前列腺特异性抗原动力学、生活质量和血液免疫反应。
主要发现
- 1a期9例在45 Gy、47.5 Gy和50 Gy剂量水平均未观察到剂量限制性毒性,未达最大耐受剂量。
- 50 Gy组1级和2级泌尿生殖毒性分别为45%和25%,1级和2级胃肠毒性分别为20%和5%,未报告≥3级毒性。
- 50 Gy组肠道生活质量基线均值(±均值标准误)为0.8(±0.8),治疗后3个月为3.5(±1.5),平均差值2.7(95%CI 0.1-5)。
- 50 Gy组国际前列腺症状评分基线均值(±均值标准误)为6.4(±0.8),治疗后3个月为7.27(±0.9),平均差值0.87(95%CI 0.3-1.9)。
- 部分患者产生针对前列腺特异性膜抗原(n=2)、前列腺酸性磷酸酶(n=1)、前列腺干细胞抗原(n=4)和前列腺特异性抗原(n=2)的抗原特异性免疫反应。
关键数值与推荐
- 全前列腺36.25 Gy/5次,同时前列腺内优势结节剂量递增至45 Gy、47.5 Gy和50 Gy(均5次)。
- 1b期推荐剂量为前列腺内优势结节50 Gy/5次。
- 剂量限制性毒性定义为首次放疗分次后90天内美国国家癌症研究所常见不良事件术语标准(版本4)≥3级胃肠或泌尿生殖毒性(或两者)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although localized prostate cancer (PCa) is multifocal, the dominant intraprostatic nodule (DIN) is responsible for disease progression after radiation therapy. PCa expresses antigens that could be recognized by the immune system. We therefore hypothesized that stereotactic dose escalation to the DIN is safe, may increase local control, and may initiate tumor-specific immune responses. PATIENTS AND METHODS: Patients with localized PCa were treated with stereotactic extreme hypofractionated doses of 36.25 Gy in 5 fractions to the whole prostate while simultaneously escalating doses to the magnetic resonance image-visible DIN (45 Gy, 47.5 Gy, and 50 Gy in 5 fractions). The phase 1a part was designed to determine the recommended phase 1b dose in a "3 + 3" cohort-based, dose-escalation design. The primary endpoint was dose-limiting toxicities defined as ≥grade 3 gastrointestinal (GI) or genitourinary (GU) toxicity (or both) by National Cancer Institute Common Terminology Criteria for Adverse Events (version 4) up to 90 days after the first radiation fraction. The secondary endpoints were prostate-specific antigen kinetics, quality of life (QoL), and blood immunologic responses. RESULTS: Nine patients were treated in phase 1a. No dose-limiting toxicities were observed at either level, and therefore the maximum tolerated dose was not reached. Further characterization of tolerability, efficacy, and immunologic outcomes was conducted in the subsequent 11 patients irradiated at the highest dose level (50 Gy) in the phase 1b expansion cohort. Toxicity was 45% and 25% for grades 1 and 2 GU, and 20% and 5% for grades 1 and 2 GI, respectively. No grade 3 or worse toxicity was reported. The average (±standard error of the mean) of the QoL assessments at baseline and at 3-month posttreatment were 0.8 (±0.8) and 3.5 (±1.5) for the bowel (mean difference, 2.7; 95% confidence interval, 0.1-5), and 6.4 (±0.8) and 7.27 (±0.9) for the International Prostate Symptom Score (mean difference, 0.87; 95% confidence interval, 0.3-1.9), respectively. A subset of patients developed antigen-specific immune responses against prostate-specific membrane antigen (n = 2), prostatic acid phosphatase (n = 1), prostate stem cell antigen (n = 4), and prostate-specific antigen (n = 2). CONCLUSIONS: Irradiation of the whole prostate with 36.25 Gy in 5 fractions and dose escalation to 50 Gy to the DIN was tolerable and determined as the recommended phase 1b dose. This treatment has promising antitumor activity, which will be confirmed by the ongoing phase 2 part. Preliminary QoL analysis showed minimal impact in GU, GI, and sexual domains. Stereotactic irradiation induced antigen-specific immune responses in a subset of patients.
引用
- Herrera FG, Valerio M, Berthold D, et al. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 30267761. doi:10.1016/j.ijrobp.2018.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。